A dedicated bone study in older adults age 55-80 (n=715), the highest dose of 300mg of canagliflozin increased serum CTX over baseline by 24.9% at 26 weeks and by 22% at 52 weeks, with P1NP decreasing by 6.9% in the highest dose group at 26 weeks. Also in the highest dose group, DEXA scanning found a decrease of 0.7% mean percent change in the lumbar spine and total hip, and quantative-CT demonstrated a decrease of 1.9% and 1.6% in the lumbar spine and total hip, respectively.